Breathtec Provides Update on FAIMS Breathalyzer Development Program
University of Florida to Complete Prototype Development
VANCOUVER, British Columbia, Nov. 05, 2018 (GLOBE NEWSWIRE) — Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company”) is pleased to report on the development of its Breathtec Disease Detection Breathalyzer (“V3”) prototype based on the FAIMS (field asymmetric waveform ion mobility spectrometry) technology. The Company announces that it has amended its research agreement with the University of Florida’s Analytical Chemistry Department, where Dr. Richard Yost, the Principal Investigator, will work to advance the V3 prototype, or future iterations, through its final stages of prototype development. Dr. Yost is one of the world’s foremost experts on FAIMS technology and has been a scientific advisor with the Company since 2016.
Before the V3 prototype development phase is successfully completed, the device will need to achieve a number of performance characteristics including device sensitivity, precision and reproducibility in a laboratory setting. Once the prototype work is completed, the device will be ready to be moved into a research use only (RUO) development phase. The goal of this phase will be to engineer and produce field ready devices that will be made available to research scientists worldwide to help advance the discovery and validation of breath-based biomarkers.
It is generally regarded within the global breath research community, that a portable, point of care breathalyzer device, that can accurately identify and quantify biomarkers in real-time, could dramatically enhance and improve the current research landscape. This advancement could possibly lead the way to regulatory approved testing.
The company’s continued support of Dr. Yost’s FAIMS research program is the result of an extensive internal review that was undertaken by the Company to identify the most cost and time effective path forward in order to achieve the goal of having an RUO device available for distribution to the research market. The Company also confirms that all collaborative research agreements with other third parties have now ended.
About Richard A. Yost Ph.D.
Dr. Yost is the University Professor and Head of Analytical Chemistry at UF, as well as the Director of the NIH Southeast Center for Integrated Metabolomics. He is highly qualified in the field of mass spectrometry, and his research has involved over 100 graduate students funded by over $50 million in research grants. He has published over 200 papers and 16 patents. Dr. Yost designed the existing triple quadrupole mass spectrometer, and over $30 billion worth of instruments have been sold based on this technology. He has served as a member of the Florida Board of Governors (Regents) and the UF Board of Trustees. He currently serves as President of the American Society for Mass Spectrometry, and has served on the editorial boards of The Journal of the American Society for Mass Spectrometry and The International Journal of Mass Spectrometry.
ABOUT BREATHTEC BIOMEDICAL INC.
Breathtec Biomedical, Inc. (“Breathtec”) is focussed on two separate core business divisions: medical devices and pharmaceutical development through drug re-purposing. Its medical device division is focused on the development of a point of care, real-time screening device for human breath analysis based on innovation and advances in the field of FAIMS (field asymmetric waveform ion mobility spectrometry) technology.
Its pharmaceutical development division is being advanced by a newly acquired subsidiary called Nash Pharmaceuticals. Nash is a clinical stage pharmaceutical development company focused on drug repurposing in the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD). Drug repurposing is the process of discovering new therapeutic uses for existing drugs.
For more information, visit www.breathtecbiomedical.com.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.